- Home
- ZYME vs PHH Comparison
ZYME vs PHH Comparison
Compare ZYME & PHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- PHH
- Stock Information
- Founded
- ZYME 2003
- PHH 2016
- Country
- ZYME United States
- PHH China
- Employees
- ZYME N/A
- PHH N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- PHH Package Goods/Cosmetics
- Sector
- ZYME Health Care
- PHH Consumer Discretionary
- Exchange
- ZYME Nasdaq
- PHH Nasdaq
- Market Cap
- ZYME 968.5M
- PHH 894.1M
- IPO Year
- ZYME 2017
- PHH 2024
- Fundamental
- Price
- ZYME $14.81
- PHH $0.50
- Analyst Decision
- ZYME Buy
- PHH
- Analyst Count
- ZYME 7
- PHH 0
- Target Price
- ZYME $20.00
- PHH N/A
- AVG Volume (30 Days)
- ZYME 453.7K
- PHH 874.3K
- Earning Date
- ZYME 08-07-2025
- PHH 08-03-2018
- Dividend Yield
- ZYME N/A
- PHH N/A
- EPS Growth
- ZYME N/A
- PHH N/A
- EPS
- ZYME N/A
- PHH N/A
- Revenue
- ZYME $122,867,000.00
- PHH $2,768,120.00
- Revenue This Year
- ZYME $107.76
- PHH N/A
- Revenue Next Year
- ZYME $2.35
- PHH N/A
- P/E Ratio
- ZYME N/A
- PHH N/A
- Revenue Growth
- ZYME 95.94
- PHH 42.65
- 52 Week Low
- ZYME $9.03
- PHH $0.46
- 52 Week High
- ZYME $17.70
- PHH $41.49
- Technical
- Relative Strength Index (RSI)
- ZYME 62.78
- PHH 27.02
- Support Level
- ZYME $13.48
- PHH $0.49
- Resistance Level
- ZYME $15.35
- PHH $0.64
- Average True Range (ATR)
- ZYME 0.58
- PHH 0.05
- MACD
- ZYME 0.10
- PHH 0.52
- Stochastic Oscillator
- ZYME 80.21
- PHH 20.37
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About PHH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.